STI571 - A new drug in treatment of chronic myeloid leukaemia;STI571 - Nowy lek w leczeniu przewlekłej białaczki szpikowej

Acta Haematologica Polonica

Volumn 32, Issue 1, 2001, Pages 5-14

  Hellman, A ^a   Prejzner, W ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

BCR ABL; Chronic myeloid leukaemia; STI571; Tyrosine kinase

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; REVIEW; TREATMENT OUTCOME;

EID: 0035181673     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Anti-fibrogenic effect of the tyrosine kinase inhibitor STI-571 on bone marrow fibrosis in chronic myeloid leukemia
2. Tyrosine protein kinase inhibition and cancer
3. Inhibition of Abl protein tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
4. In vivo eradication of human Bcr-Abl positive leukemia cells with an Abl kinase inhibitor
5. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
6. Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome
7. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of bcr/abl positive cells
8. Bcr-Abl tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia
9. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
10. Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
11. Status of BcrAbl tyrosine kinase inhibitors in chronic myelogenous leukemia
12. CGP57148B(STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl positive human leukemia cells to apoptosis due to antileukemic drugs
13. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis
14. Tyrosine - Kinase inhibition in treatment of chronic myeloid leukemia
15. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
16. Biologia molekularna przewickłej białaczki szpikowej
17. Od kinazy fosoforylazy... do tysia̧c i jednej białkowej kinazy?
18. Phase II study of STI 571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome - positive chronic myeloid leukemia (Ph+CML)
19. Prolonged survival in chronic myelogenous leukemia alter cytogenetic response to interferon α therapy
20. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products
21. Selection and charakterization of Bcr/abl positive cell lines with differential sensivitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
22. Chronic myelogenous leukemia
23. A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias
24. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
25. Characterization of the clinical response to STI571: Biochemical evaluation of response and resistant advanced stage chronic myelogenous leukemia patients
26. Activity of an Abl specific tyrosine kinase inhibitor in patients with Bcr/Abl positive acute leukemias including chronic myelogenous leukemia in blast crisis
27. A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
28. Response of STI571 - Resistant cells to other chemotherapeutic drugs and signal transduction inhibitors
29. Mechanism of resistance to the Abl tyrosine kinase inhibitor STI571 in Bcr/abl transformed hematopoietic cell lines
30. Blocking of EGF- Dependent cell proliferation by EFG receptor kinase inhibitors